Bristol-Myers Squibb (NYS: BMY) is expected to report Q3 earnings on Oct. 24. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bristol-Myers Squibb's revenues will drop -25.8% and EPS will contract -31.1%.
The average estimate for revenue is $3.97 billion. On the bottom line, the average EPS estimate is $0.42.
Last quarter, Bristol-Myers Squibb logged revenue of $4.44 billion. GAAP reported sales were 18% lower than the prior-year quarter's $5.43 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.48. GAAP EPS of $0.38 for Q2 were 27% lower than the prior-year quarter's $0.52 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.3%, 220 basis points better than the prior-year quarter. Operating margin was 27.1%, 630 basis points worse than the prior-year quarter. Net margin was 14.5%, 210 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $17.92 billion. The average EPS estimate is $1.93.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,699 members out of 1,809 rating the stock outperform, and 110 members rating it underperform. Among 476 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 457 give Bristol-Myers Squibb a green thumbs-up, and 19 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is hold, with an average price target of $34.85.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
Add Bristol-Myers Squibb to My Watchlist.
The article Bristol-Myers Squibb Earnings Up Next originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.